Explore

Trendline Trendline
Veradermics Announces Conference Call to Discuss Phase 2/3 Study Results for Hair Loss Treatment

Veradermics Announces Conference Call to Discuss Phase 2/3 Study Results for Hair Loss Treatment

Veradermics Announces Conference Call to Discuss Phase 2/3 Study Results for Hair Loss Treatment
Trendline Trendline
ADC Therapeutics Announces First Quarter 2026 Financial Results Call

ADC Therapeutics Announces First Quarter 2026 Financial Results Call

ADC Therapeutics Announces First Quarter 2026 Financial Results Call
Rapid Read Rapid Read
FDA Approves New Quadruplet Regimen for Transplant-Ineligible Multiple Myeloma Patients

FDA Approves New Quadruplet Regimen for Transplant-Ineligible Multiple Myeloma Patients

The U.S. Food and Drug Administration (FDA) has approved a new treatment regimen for adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT). The regimen, known as DVRd, combines DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) with bortezomib, lenalidomide, and dexamethasone. This approval is based on the Phase 3 CEPHEUS study, which demonstrated a significant improvement in minimal residual disease (MRD)-negativity rates compared to the previous standard regimen. The study showed that DVRd achieved a 52.3% MRD-negativity rate at a median follow-up of 22 months, compared to 34.8% with the previous regimen. This marks the third indication for DARZALEX FASPRO® in transplant-ineligible patients, reinforcing its role in the treatment landscape for multiple myeloma.
Trendline Trendline
Xcovery and EVERSANA Partner to Launch Lung Cancer Drug Ensacove in U.S.

Xcovery and EVERSANA Partner to Launch Lung Cancer Drug Ensacove in U.S.

Xcovery and EVERSANA Partner to Launch Lung Cancer Drug Ensacove in U.S.
Rapid Read Rapid Read
FDA Approves AstraZeneca's Saphnelo Pen for Self-Administration in Lupus Treatment

FDA Approves AstraZeneca's Saphnelo Pen for Self-Administration in Lupus Treatment

AstraZeneca's Saphnelo (anifrolumab) has received approval from the U.S. Food and Drug Administration (FDA) for self-administration as a once-weekly autoinjector, known as the Saphnelo Pen, for adults with systemic lupus erythematosus (SLE). This decision follows the successful Phase III TULIP-SC trial, which showed that subcutaneous administration of Saphnelo significantly reduced disease activity in patients with moderate to severe SLE. The trial's findings, published in Arthritis & Rheumatology, confirmed the safety and efficacy of the autoinjector, aligning with the known profile of Saphnelo when given intravenously. This approval is expected to enhance treatment accessibility and convenience for lupus patients.
Rapid Read Rapid Read
Remote Robotic Surgery Conducted from Florida to Angola Marks Healthcare Milestone

Remote Robotic Surgery Conducted from Florida to Angola Marks Healthcare Milestone

A groundbreaking remote robotic surgery was successfully conducted by Dr. Vipul Patel, the medical director of the Global Robotic Institute at Advent Health in Orlando, Florida. The procedure involved a patient in Angola diagnosed with prostate cancer, with Dr. Patel operating from 7,000 miles away. This surgery is part of a human clinical trial approved by the U.S. Food and Drug Administration to test the feasibility of transcontinental robotic telesurgery. The use of a multimillion-dollar robotic system allowed for a less invasive and more precise procedure, which typically results in faster recovery times. The trial aims to explore the potential of such technology to provide surgical care in underserved areas globally and in rural parts of the U.S.
Trendline Trendline
Ascletis Completes Enrollment in U.S. Phase II Study of ASC30 for Diabetes Treatment

Ascletis Completes Enrollment in U.S. Phase II Study of ASC30 for Diabetes Treatment

Ascletis Completes Enrollment in U.S. Phase II Study of ASC30 for Diabetes Treatment
Rapid Read Rapid Read
Former Senator Ben Sasse Attributes Extended Life to Experimental Cancer Treatment

Former Senator Ben Sasse Attributes Extended Life to Experimental Cancer Treatment

Former U.S. Senator Ben Sasse, diagnosed with stage 4 metastatic pancreatic cancer, credits an experimental drug for extending his life beyond initial expectations. Diagnosed in December and given a prognosis of three to four months, Sasse has seen a 76% reduction in tumor size due to a clinical trial involving the drug daraxonrasib. This treatment, developed by Revolution Medicines, has extended the life expectancy of patients from six to approximately thirteen months. Sasse discussed his journey and the impact of this treatment in an interview with Scott Pelley on '60 Minutes,' highlighting the role of faith and medical innovation in his ongoing battle with cancer.
Rapid Read Rapid Read
Former Senator Ben Sasse Credits Miracle Drug for Extending Life Amid Cancer Battle

Former Senator Ben Sasse Credits Miracle Drug for Extending Life Amid Cancer Battle

Former U.S. Senator Ben Sasse, diagnosed with stage 4 metastatic pancreatic cancer, has experienced a significant extension of life due to a clinical trial drug. Initially given only a few months to live, Sasse attributes his extended survival to 'providence, prayer, and a miracle drug' that has reduced his tumors by 76%. The drug, daraxonrasib, developed by Revolution Medicines, has shown promise in extending the lives of patients with similar diagnoses. Sasse discussed his health journey and the state of American politics in an interview with Scott Pelley on '60 Minutes,' expressing concerns about the lack of long-term vision in Congress.
Trendline Trendline
Anaxiom Corporation Reports Promising Results from Minimally Invasive Obesity Device Study

Anaxiom Corporation Reports Promising Results from Minimally Invasive Obesity Device Study

Anaxiom Corporation Reports Promising Results from Minimally Invasive Obesity Device Study
Rapid Read Rapid Read
Glioblastoma Multiforme: Understanding the Challenges of the Most Aggressive Brain Cancer

Glioblastoma Multiforme: Understanding the Challenges of the Most Aggressive Brain Cancer

Glioblastoma multiforme (GBM) is recognized as the most aggressive and lethal brain tumor in adults, posing significant challenges to patient survival. Despite multimodal treatment approaches, including the use of temozolomide and radiotherapy, the median survival for patients diagnosed with glioblastoma remains approximately 12-15 months. GBM is a grade 4 astrocytoma, the highest grade and most malignant type of primary brain tumor. It represents about half of all primary central nervous system malignancies, with an annual incidence of approximately 3 cases per 100,000 people in the United States. The tumor is characterized by rapid growth and extensive infiltration into surrounding brain tissue, making complete surgical removal impossible. GBM's cellular heterogeneity and the presence of glioma stem cells contribute to its resistance to conventional therapies.
Trendline Trendline
FDA Approves First Human Trial of Ibogaine Derivative for Mental Health Treatment

FDA Approves First Human Trial of Ibogaine Derivative for Mental Health Treatment

FDA Approves First Human Trial of Ibogaine Derivative for Mental Health Treatment